Caption Management’s Crescent Biopharma CBIO Stock Holding History

Caption Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,105	Closed	-$139K	–	1223
2023 Q1	$139K	Buy	+1,105	New	+$249K	﹤0.01%	945

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's CBIO Position: Q2 2023 in Review

Caption Management sold out of Crescent Biopharma (CBIO) in Q2 2023, closing a stake of 67 shares — an estimated $8.39K sold.

Caption Management first reported a position in CBIO in Q2 2019 and held it in 4 quarters. The position peaked at $458K in Q3 2020. 55 funds tracked by Wall St. Rank hold CBIO as of Q2 2023.

Caption Management reported no remaining Crescent Biopharma position as of Q2 2023 after selling out during the quarter.
Caption Management sold 67 Crescent Biopharma shares in Q2 2023, an estimated $8.39K.
Caption Management first reported a position in Crescent Biopharma in Q2 2019 and held it in 4 quarters.
Caption Management's Crescent Biopharma position peaked at $458K in Q3 2020.
55 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2023.

Based on Caption Management's 13F filing for Q2 2023, filed 14 Aug 2023.